THERAPY DOSSIER · th-80e820f3d103

CN-100 (2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic acid)

Drug · No ChEMBL mechanism_of_action record; USAN stem -profen (anti-inflammatory/analgesic, ibuprofen type).

Evidence & regulatory context

Mechanism: No ChEMBL mechanism_of_action record; USAN stem -profen (anti-inflammatory/analgesic, ibuprofen type).
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL1765291 ↗
ChEMBL max phase: 2 / 4 (development scale, not regulatory approval)
Synonyms: CN-100; Zaltoprofen; Peon; Soreton; Zaltoprofene
Note: Not recorded

Clinical trials 1

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT01369238 ↗Injury indicationNAunknown

Bee-venom acupuncture therapy vs zaltoprofen in whiplash-associated disorders after traffic collisions

Whiplash Injuries

Enrolment: 90 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 3566841 ↗1986Mixed findings

Pharmacological investigations of the new antiinflammatory agent 2-(10,11-dihydro-10-oxodibenzo[b,f]thiepin-2-yl)propionic acid. 3rd communication: inhibitory effects on leucocyte emigration and proliferation of granulation.

RatOthermale

Model: Carrageenin pleurisy, carboxymethylcellulose pouch, and paper disk granulation models of inflammation and granulation tissue formation

CN-100 inhibited protein exudation and polymorph emigration at 6 h and monocyte emigration at 24 h, with activity approximately equal to pranoprofen and weaker than indometacin. It also inhibited granulation tissue proliferation, that is it inhibited wound healing, again comparable to pranoprofen a…

Extraction: extract · Supplied extraction confidence: 0.65. Machine-extracted fields require source verification.

Loading the evidence…